NYSE:IBIO iBio (IBIO) Stock Price, News & Analysis → Buy this small stock before coming AI Tidal Wave (From Chaikin Analytics) (Ad) Free IBIO Stock Alerts $2.23 -0.24 (-9.72%) (As of 05/30/2024 ET) Add Compare Share Share Today's Range$2.23▼$2.4550-Day Range$1.26▼$4.0652-Week Range$1.02▼$17.60Volume129,429 shsAverage Volume2.39 million shsMarket Capitalization$19.23 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsOwnershipSEC FilingsTrends iBio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside124.2% Upside$5.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.07 out of 5 starsMedical Sector814th out of 930 stocksPharmaceutical Preparations Industry386th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingiBio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageiBio has only been the subject of 1 research reports in the past 90 days.Read more about iBio's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IBIO. Previous Next 0.0 Dividend Strength Dividend YieldiBio does not currently pay a dividend.Dividend GrowthiBio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IBIO. Previous Next 1.9 News and Social Media Coverage News SentimentiBio has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for iBio this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for IBIO on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, iBio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.12% of the stock of iBio is held by insiders.Percentage Held by InstitutionsOnly 7.90% of the stock of iBio is held by institutions.Read more about iBio's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioiBio has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. About iBio Stock (NYSE:IBIO)iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Read More IBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IBIO Stock News HeadlinesMay 29 at 3:18 AM | americanbankingnews.comiBio (NYSE:IBIO) Receives New Coverage from Analysts at Chardan CapitalMay 14, 2024 | finanznachrichten.deiBio, Inc.: iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | globenewswire.comiBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate UpdateApril 5, 2024 | investorplace.com3 Healthcare Stocks Short Sellers Are Prescribing for TroubleMarch 28, 2024 | markets.businessinsider.comKodiak Sciences Inc Registered Shs hosts conference call for investorsSee More Headlines Company Calendar Last Earnings5/13/2024Today5/30/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:IBIO Previous SymbolNYSE:IBIO CUSIPN/A CIK1420720 Webwww.ibioinc.com Phone302-355-0650Fax302-356-1173Employees26Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+124.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,010,000.00 Net MarginsN/A Pretax Margin-34,258.00% Return on Equity-109.36% Return on Assets-42.02% Debt Debt-to-Equity Ratio0.04 Current Ratio1.69 Quick Ratio1.69 Sales & Book Value Annual Sales$50,000.00 Price / Sales384.63 Cash FlowN/A Price / Cash FlowN/A Book Value$2.88 per share Price / Book0.77Miscellaneous Outstanding Shares8,624,000Free Float8,527,000Market Cap$19.23 million OptionableN/A Beta-3.22 Key ExecutivesDr. Martin B. Brenner D.V.M. (Age 53)Ph.D., CEO & Chief Scientific Officer Comp: $577.31kMr. Felipe Duran (Age 44)Chief Financial Officer Comp: $1.07MStephen KilmerInvestor Relations OfficerMr. Marc Banjak J.D.General CounselMr. Robert B. Kay (Age 84)Interim Secretary & Interim Treasurer Comp: $92.69kKey CompetitorsSensei BiotherapeuticsNASDAQ:SNSEMEI PharmaNASDAQ:MEIPNeuroBo PharmaceuticalsNASDAQ:NRBOIndaptus TherapeuticsNASDAQ:INDPCumberland PharmaceuticalsNASDAQ:CPIXView All CompetitorsInstitutional OwnershipLynx1 Capital Management LPBought 600,000 shares on 5/30/2024Ownership: 6.957%Opaleye Management Inc.Bought 680,000 shares on 5/29/2024Ownership: 7.889%Ikarian Capital LLCBought 600,000 shares on 5/17/2024Ownership: 6.961%View All Institutional Transactions IBIO Stock Analysis - Frequently Asked Questions Should I buy or sell iBio stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iBio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IBIO shares. View IBIO analyst ratings or view top-rated stocks. What is iBio's stock price target for 2024? 1 brokers have issued 1 year price targets for iBio's shares. Their IBIO share price targets range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 124.2% from the stock's current price. View analysts price targets for IBIO or view top-rated stocks among Wall Street analysts. How have IBIO shares performed in 2024? iBio's stock was trading at $1.26 at the beginning of the year. Since then, IBIO shares have increased by 77.0% and is now trading at $2.23. View the best growth stocks for 2024 here. How were iBio's earnings last quarter? iBio, Inc. (NYSE:IBIO) issued its quarterly earnings results on Monday, May, 13th. The company reported ($0.71) earnings per share for the quarter. What other stocks do shareholders of iBio own? Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Sorrento Therapeutics (SRNE), Tesla (TSLA), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Arista Networks (ANET), Aquestive Therapeutics (AQST), Alphatec (ATEC), Alibaba Group (BABA), Boxlight (BOXL) and Ford Motor (F). Who are iBio's major shareholders? iBio's stock is owned by a number of retail and institutional investors. Top institutional investors include Opaleye Management Inc. (7.89%), Lynx1 Capital Management LP (6.96%) and Ikarian Capital LLC (6.96%). How do I buy shares of iBio? Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:IBIO) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBill Clinton Backing Biden Replacement???The Freeport SocietyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarElon Musk’s Final Masterpiece: “X-9840”Paradigm PressGold Set to EXPLODE!Gold Safe ExchangeUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin Pro Adding Choose a watchlist: Watchlist My Default Watchlist Adding iBio, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
